Although clinical studies on CD80 expression on CD62L+ pDCs are scarce, the findings of the study on its pro-tumorigenic effects in malignant thymomas provide a theoretical foundation for future targeted immunotherapy. This evidence concerns the gene CD80 and thymic carcinoma.